‘Killer’ immunotherapy shows early promise
April 11, 2022Sales and Marketing
A first of its kind immunotherapy which uses the immune system’s ‘natural killer cells’ could offer potential against a range …
NICE publishes guidance for atopic dermatitis treatments
April 8, 2022Medical Communications
Abrocitinib, upadacitinib, and tralokinumab are not recommended for treating moderate to severe atopic dermatitis. The recommendation does not affect patients …
First-of-its-kind vaccine manufacturing facility shipped to Africa
April 8, 2022Medical Communications
KeyPlants announced the shipping a first-of-its-kind vaccine manufacturing filling facility to Senegal, in West Africa.
Acadia seeks first-ever FDA approval in Rett Syndrome
April 8, 2022Medical Communications
Acadia has presented an update on its Phase III LAVENDER study of trofinetide for Rett Syndrome at the American Academy …
Kintor’s antiviral shows protection in mild-to-moderate COVID-19
April 7, 2022Business Services
Kintor Pharmaceutical, based in Suzhou, China, has announced top-line results from its Phase III MRCT trial of proxalutamide in outpatients …
Blood clot risk higher for six months after having COVID-19
April 7, 2022Business Services
A study from Sweden suggests that after a COVID-19 infection, there is an increased risk of developing a serious blood …
Eligible patients in the UK granted early access for radioligand therapy in advanced prostate cancer
April 7, 2022Business Services
Advanced Accelerator Applications (AAA), a Novartis company, has announced that eligible patients in the UK have been granted early access …
Global Paediatric Drug Development Centre of Excellence opened in Dublin’s North Dock
April 7, 2022Business Services
Gilead Sciences announced on April 6th the formal opening of its Dublin city centre office, focused on developing new paediatric …
Nine more COVID-19 symptoms added to list
April 6, 2022Research and Development
Nine new symptoms, including sore throat, fatigue, and headache, have been added to the official list of COVID-19 symptoms on …
UK Government accused of failing to address cancer staff shortages
April 6, 2022Research and Development
MPs have warned that urgent steps are needed to prevent the UK from losing gains made in recent years on …
New variant, Omicron XE, detected in UK
April 6, 2022Research and Development
A new sub-variant of Omicron has been found in the UK, as the country experiences a new surge of COVID-19.The …
Race to deliver HIV drugs to Ukraine
April 6, 2022Research and Development
WHO is to supply thousands of antiretroviral drugs to Ukraine for patients living with HIV over the next year. UNAIDS, …
European Commission approves treatment of unresectable uveal melanoma
April 5, 2022Manufacturing and Production
Immunocore Holdings has announced that the European Commission has approved KIMMTRAK® (tebentafusp) for the treatment of HLA-A*02:01-positive adult patients with …
Technology enabling thermally-controlled DNA synthesis
April 5, 2022Manufacturing and Production
Evonetix has been granted a patent in Europe for thermal control technology for DNA synthesis, as well as the design …
NHS struggling to make progress on early cancer diagnosis
April 5, 2022Manufacturing and Production
MPs have warned that the NHS in England is struggling to make progress on its flagship target to diagnose three-quarters …
FDA approves generic version of brain imaging agent in US
April 5, 2022Manufacturing and Production
The FDA has approved the generic version of DaTscan (Ioflupane I 123), manufactured and commercialised by Curium. This is a …
FlyPharma Conference Europe: New dates and location announced
April 4, 2022Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
FlyPharma Conferences are pleased to announce that FlyPharma Europe is returning as a live, in-person event in 2022.
AI test could predict effective cancer drug combinations in less than two days
April 4, 2022Sales and Marketing
Scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in …
FDA accepts Dupixent for Priority Review in patients 12+ with eosinophilic esophagitis
April 4, 2022Sales and Marketing
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab), in patients aged 12 …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
